Tenderwize
Retour à la recherche

Pharmaceutical products with active substance Tolvaptan

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Jun 29, 2027 · 305 days left·Open·Supplies
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Tolvaptan (ATC: G04BX21 - ausgenommen Arzneimittel mit einheitlichen Wirkstärken)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed minimum volume or estimated value; the tender does not provide any indication of potential revenue.

Contracts may be terminated if the buyer later awards exclusive contracts for the same active substance.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for Tolvaptan (ATC G04BX21) finished medicinal products
  • Open-house model: any qualified pharmaceutical company can join
Afficher le résumé complet

This is an open-house model for non-exclusive discount agreements for Tolvaptan (ATC G04BX21) in Germany, administered by AOK Sachsen-Anhalt. It is not a typical public procurement but a transparent process for any qualified pharmaceutical company to join a discount agreement under §130a Abs. 8 SGB V. The contract duration is 24 months (01.09.2025 to 31.08.2027). No estimated value is provided. Documents are available but not analyzed. Submission is possible via platform (with QES) or postal mail.

Risques

No guaranteed minimum volume or estimated value; the tender does not provide any indication of potential revenue.

Contracts may be terminated if the buyer later awards exclusive contracts for the same active substance.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Administrative

  • Pharmaceutical companies must request and complete the participation documents
  • Documents must be fully completed and signed
  • Submission via platform with qualified electronic signature or postal mail

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; all qualified participants receive a contract.

Acheteur

Localisation

Magdeburg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258393558

Activité

Health

Lots (1)

LOT-0001

Pharmaceutical products with active substance Tolvaptan

Non-exclusive discount agreements for finished medicinal products containing Tolvaptan (ATC G04BX21, excluding uniform strengths). Open-house model with no exclusivity, individual negotiations, or minimum volume. Contract duration 24 months starting 01.09.2025, ending 31.08.2027. Early termination possible if exclusive contracts are awarded.

SuppliesEU fundedElectronic submission

Localisation

DEE03, Germany

Durée

2 YEAR

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; all qualified participants receive a contract.

Date limite

Deadline Jun 30, 2027

Détails de la procédure

Date de publication
13 Jul 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
457338-2025

Documents (1)

Appels d'offres similaires